Enhancing Targeted Payload Delivery via Novel Receptor-Mediated Internalization to Mitigate Toxicity in Next-Generation ADCs

• Leveraging a novel receptor-driven internalization mechanism to enable rapid, tumor-specific payload delivery, reducing systemic exposure and off-target toxicity compared to traditional ADCs
• Utilizing PDC architecture to achieve differentiated pharmacokinetics and improved safety profiles, addressing challenges associated with dual payloads and complex ADC formats
• Activating multimodal mechanisms of action to enhance efficacy while enabling safer combination strategies

Speakers:

Christian Marsolais

Senior Vice President & Chief Medical Officer

Theratechnologies